Valuation: Fennec Pharmaceuticals Inc.

Market Cap 372M 334M 309M 280M 523M 35.47B 529M 3.69B 1.47B 18.56B 1.4B 1.37B 58.92B P/E 2026 *
35.4x
P/E 2027 * 10.7x
Enterprise Value 372M 334M 309M 280M 523M 35.47B 529M 3.69B 1.47B 18.56B 1.4B 1.37B 58.92B EV / Sales 2026 *
5.13x
EV / Sales 2027 * 3.61x
Free-Float
78.7%
Yield 2026 *
-
Yield 2027 * -
1 day+2.35%
1 week+4.72%
Current month+2.07%
1 month-0.73%
3 months+9.36%
6 months+62.24%
Current year+41.17%
1 week 9.93
Extreme 9.93
10.89
1 month 9.87
Extreme 9.87
11.11
Current year 5.65
Extreme 5.65
13.25
1 year 5.65
Extreme 5.65
13.25
3 years 3.96
Extreme 3.96
13.25
5 years 3.82
Extreme 3.8219
13.25
10 years 1.64
Extreme 1.6439
14.99
Manager TitleAgeSince
Chief Executive Officer 64 16/08/2024
Director of Finance/CFO 51 06/01/2010
Chief Tech/Sci/R&D Officer 51 28/10/2024
Director TitleAgeSince
Director/Board Member 72 25/08/2011
Chairman 69 09/12/2015
Director/Board Member 70 10/08/2016
Date Insider Type Main position Quantity % Market Cap. Importance
12/10/26 Free

Executive/Senior Manager

2,326 0.0066%
12/10/26 Free

Chief Executive Officer

2,224 0.0063%
12/10/26 Free

Chief Financial Officer

3,846 0.0110%
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+4.72%+24.09%+57.99% 372M
+0.50%+1.38%+57.09%+127.73% 1,143B
+0.86%+5.14%+45.00%+84.34% 647B
-0.14%+0.42%+25.69%+101.56% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-5.97%+61.93%+37.25% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+3.08%+54.69%+71.67% 242B
+0.08%+3.67%+35.05%+104.71% 197B
Average +0.69%+0.91%+37.97%+73.33% 402.79B
Weighted average by Cap. +0.77%+0.71%+43.68%+87.35%

Financials

2026 *2027 *
Net sales 72.56M 65.1M 60.19M 54.51M 102M 6.91B 103M 720M 287M 3.62B 272M 267M 11.48B 103M 92.51M 85.53M 77.46M 145M 9.82B 146M 1.02B 407M 5.14B 387M 379M 16.31B
Net income 10.48M 9.4M 8.69M 7.87M 14.71M 998M 14.89M 104M 41.4M 522M 39.32M 38.49M 1.66B 35.13M 31.52M 29.14M 26.39M 49.3M 3.35B 49.9M 348M 139M 1.75B 132M 129M 5.56B
Net Debt - -
Projected Income Statement - Annual - Fennec Pharmaceuticals Inc.
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
29/10/26 $10.87 +2.35% 137,198
27/10/26 $10.62 +4.63% 93,186
26/10/26 $10.15 +0.69% 115,942
23/10/26 $10.08 -2.33% 70,820
22/10/26 $10.32 -0.58% 104,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Fennec Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.62USD
Average target price
17.67USD
Spread / Average Target
+66.35%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fennec Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. FENC Stock